GERMANTOWN, Md., Jan. 19, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON) announced today the closing of its previously announced underwritten public offering of common stock. Intrexon sold 6,900,000 shares of its common stock at a public offering price of $12.50 per share, including the exercise in full by the underwriters of their option to purchase an additional 900,000 shares of common stock. Gross proceeds to Intrexon from the offering are expected to be approximately $86 million before deducting the underwriting discount and other offering expenses payable by Intrexon.JMP Securities LLC acted as sole book-running manager and Stifel acted as lead manager for the offering. Northland Capital Markets acted as co-manager for the offering.The public offering was made pursuant to an automatic shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC) and became effective on September 1, 2017. A final prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the website of the SEC at www.sec.gov. Copies of the final prospectus supplement and accompanying base prospectus relating to the offering may also be obtained from JMP Securities LLC, 600 Montgomery Street, Suite 1100, San Francisco, California 94111, Attention: Prospectus Department, by calling +1 (415) 835-8985, or by email at syndicate@jmpsecurities.com.This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Intrexon CorporationIntrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet. Intrexon's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells.TrademarksIntrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.Forward-Looking Safe Harbor Statement:This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which involve risks and uncertainties, including statements regarding the proposed public offering. Various factors may cause differences between Intrexon's expectations and actual results, including risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering. More information about potential factors that could affect Intrexon's business and financial results is contained in its annual report on Form 10-K, its quarterly reports on Form 10-Q and other filings with the SEC. Intrexon does not intend, and undertakes no duty, to update this information to reflect future events or circumstances.For more information about Intrexon Corporation, contact:Investor Contact:Thomas Shrader, PhDVice President, Communications & StrategyIntrexon Corporationinvestors@intrexon.comCorporate Contact:Marie Rossi, PhDDirector, Technical CommunicationsIntrexon CorporationTel: +1 (301) 556-9850publicrelations@intrexon.com